BACKGROUND: Gefitinib (Iressa) is active as a single agent in the treatment of select patients with recurrent non-small cell lung cancer (NSCLC). The clinical characteristics of patients treated with gefitinib on an Expanded Access Program (EAP) at our institution identified predictive variables associated with better outcome. PATIENTS AND METHODS: Patients (n=199) with advanced NSCLC were treated with gefitinib (250 mg) upon progression with chemotherapy. Baseline patient characteristics were: median age, 69 years; males, 57%; adenocarcinoma, 56%. RESULTS: Partial responses were noted in two patients (1%) and disease stabilization in 66 (35%) patients. The median survival (MS) was 5.9 months [95% confidence interval (CI) 4.1-7.1] and median time to progression was 3 months (95% CI 2.0-3.0). The predictive factors analyzed were gender, skin rash, diarrhea, tumor histology and performance status (PS). Patients who developed skin rash (any grade) had MS of 10.8 months versus 4.0 months for those without rash (P <0.0001, log rank test). Patients with PS 0, 1 and 2 had MS of 8.4, 6.2 and 2.8 months, respectively (P <0.0002). The other factors did not impact survival. CONCLUSIONS: Occurrence of skin rash and baseline PS of 0/1 were associated with improved survival with gefitinib for recurrent NSCLC patients at our institution.
BACKGROUND:Gefitinib (Iressa) is active as a single agent in the treatment of select patients with recurrent non-small cell lung cancer (NSCLC). The clinical characteristics of patients treated with gefitinib on an Expanded Access Program (EAP) at our institution identified predictive variables associated with better outcome. PATIENTS AND METHODS: Patients (n=199) with advanced NSCLC were treated with gefitinib (250 mg) upon progression with chemotherapy. Baseline patient characteristics were: median age, 69 years; males, 57%; adenocarcinoma, 56%. RESULTS: Partial responses were noted in two patients (1%) and disease stabilization in 66 (35%) patients. The median survival (MS) was 5.9 months [95% confidence interval (CI) 4.1-7.1] and median time to progression was 3 months (95% CI 2.0-3.0). The predictive factors analyzed were gender, skin rash, diarrhea, tumor histology and performance status (PS). Patients who developed skin rash (any grade) had MS of 10.8 months versus 4.0 months for those without rash (P <0.0001, log rank test). Patients with PS 0, 1 and 2 had MS of 8.4, 6.2 and 2.8 months, respectively (P <0.0002). The other factors did not impact survival. CONCLUSIONS: Occurrence of skin rash and baseline PS of 0/1 were associated with improved survival with gefitinib for recurrent NSCLCpatients at our institution.
Authors: Huixin Yu; Neeltje Steeghs; Cynthia M Nijenhuis; Jan H M Schellens; Jos H Beijnen; Alwin D R Huitema Journal: Clin Pharmacokinet Date: 2014-04 Impact factor: 6.447
Authors: Aaron Lisberg; D Andrew Tucker; Jonathan W Goldman; Brian Wolf; James Carroll; Ariana Hardy; Karolyn Morris; Paulina Linares; Carlos Adame; Marshall L Spiegel; Courtney Wells; Jordan McKenzie; Blanca Ledezma; Melody Mendenhall; Phillip Abarca; Krikor Bornazyan; Jaime Hunt; Nima Moghadam; Natalie Chong; Danielle Nameth; Caitlin Marx; John Madrigal; Sitaram Vangala; Narek Shaverdian; David Elashoff; Edward B Garon Journal: Cancer Immunol Res Date: 2018-01-30 Impact factor: 11.151
Authors: Anu Osinusi; Joseph J Rasimas; Rachel Bishop; Michael Proschan; Mary McLaughlin; Alison Murphy; Karoll J Cortez; Michael A Polis; Henry Masur; Donald Rosenstein; Shyam Kottilil Journal: J Acquir Immune Defic Syndr Date: 2010-03 Impact factor: 3.731
Authors: Yun-Hong Cheon; Moon Jin Kim; Min Gyu Kang; Hee Jin Kim; Sang Su Lee; Cha Young Kim; Dae-Hong Jeon; Yu Eun Kim; Gyeong-Won Lee Journal: Yonsei Med J Date: 2011-07 Impact factor: 2.759